在外围T细胞淋巴瘤患者中,现实世界的治疗模式,医疗资源利用和成本
Charles Dharmani1, Sudhir Unni1, Ngan Pham2
1Daiichi Sankyo, Inc., 211 Mount Airy Road, Basking Ridge, NJ 07920, USA.
Future oncology (London, England)
|October 10, 2023
概括
这项研究分析了美国T细胞淋巴瘤 (PTCL) 患者的治疗模式和成本. 研究结果显示,组合疗法在一线治疗中很常见,在随后的治疗线上,成本会增加.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
背景情况:
- 周围T细胞淋巴瘤 (PTCL) 是一种异质的非霍奇金淋巴瘤群.
- 了解治疗模式和相关成本对于管理PTCL患者至关重要.
研究的目的:
- 评估美国PTCL患者的治疗模式,医疗资源利用率 (HRU) 和成本.
- 分析一线 (1LOT),二线 (2LOT) 和第三线或之后 (≥3LOT) 治疗中的治疗和成本差异.
主要方法:
- 使用IQVIA PharMetrics® Plus索赔数据库 (2011年4月至2021年11月) 进行的回顾性队列研究.
- 识别了接受全身治疗的PTCL患者,分为1LOT,2LOT和≥3LOT亚队列.
- 估计的常见治疗方案,治疗时间,HRU和成本.
主要成果:
- 分析了189名PTCL患者,61.9%接受1LOT,21.7%接受2LOT,16.4%接受≥3LOT.
- 第一线治疗包括CHOP/CHOP类,CHOEP/CHOEP类和布伦图西马布维多丁;单一疗法在后一线中占主导地位.
- 所有原因和PTCL相关的HRU和成本随着每次后续的治疗线增加.
结论:
- 治疗模式因治疗线而异,在1LOT中使用组合疗法,在随后的LOT中使用单一疗法.
- 外围T细胞淋巴瘤的治疗与大量的医疗费用有关,近70%的医疗费用归因于该疾病.
关键词:
羊群 羊群 羊群 羊群 羊群 羊群在CHOP中使用CHOP.布伦图克西马巴 (brentuximab) 是一个医疗保健费用 医疗保健费用医疗保健资源利用率 医疗保健资源利用率这些线路的疗法.其他非霍奇金淋巴瘤.周围T细胞淋巴瘤现实世界的研究研究.治疗模式 治疗模式更多相关视频
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
399
14:45Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
15.0K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
539
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
539
